Biomimetic nanoparticles for inflammation targeting

Jin, Kai; Luo, Zimiao; Zhang, Bo; Pang, Zhiqing

doi:10.1016/j.apsb.2017.12.002

Cited by 267 publications

(185 citation statements)

References 101 publications

Supporting

Mentioning

185

Contrasting

Order By: Relevance

“…The naïve macrophage (M/) EVs can penetrate through the BBB in mammals. The mechanism might be that these EVs contain integrin lymphocyte function-associated antigen 1 (LFA-1), intercellular adhesion molecule 1 (ICAM-1) (Jin et al, 2018), and carbohydrate-binding C-type lectin receptors (Aranda-Souza et al, 2019), that can interact with brain vessel endothelial cells comprising the BBB (Yuan et al, 2017). Notably, upregulation of ICAM-1, a common process in inflammation, promoted M/ EVs' uptake by BBB.…”

Section: Macrophagesmentioning

confidence: 99%

Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source

et al. 2020

View full text Add to dashboard Cite

Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, are nanosized membrane vesicles derived from most cell types. Carrying diverse biomolecules from their parent cells, EVs are important mediators of intercellular communication and thus play significant roles in physiological and pathological processes. Owing to their natural biogenesis process, EVs are generated with high biocompatibility, enhanced stability, and limited immunogenicity, which provide multiple advantages as drug delivery systems (DDSs) over traditional synthetic delivery vehicles. EVs have been reported to be used for the delivery of siRNAs, miRNAs, protein, small molecule drugs, nanoparticles, and CRISPR/Cas9 in the treatment of various diseases. As a natural drug delivery vectors, EVs can penetrate into the tissues and be bioengineered to enhance the targetability. Although EVs' characteristics make them ideal for drug delivery, EV-based drug delivery remains challenging, due to lack of standardized isolation and purification methods, limited drug loading efficiency, and insufficient clinical grade production. In this review, we summarized the current knowledge on the application of EVs as DDS from the perspective of different cell origin and weighted the advantages and bottlenecks of EV-based DDS. ARTICLE HISTORY

show abstract

Section: Macrophagesmentioning

confidence: 99%

Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source

et al. 2020

View full text Add to dashboard Cite

show abstract

“…First of all, in this way it is possible to localize the drug in the body area of interest and to extend the release period. Moreover, the interaction of the drug with other tissues and the risk of side effects can be limited: because of this, a more uniform drug distribution is provided and a smaller quantity of drug is needed because of the limited losses of pharmaceutical product elsewhere in the body [56,57]. In order to achieve the targeted delivery, more difficult synthesis methods are required, which commonly involve more steps for the synthesis of the final nanoparticle, also including much more time and higher costs.…”

Section: Targeted Drug Delivery: Selectivity Of the Delivery Process mentioning

confidence: 99%

Coating and Functionalization Strategies for Nanogels and Nanoparticles for Selective Drug Delivery

Pinelli

Perale

Rossi

2020

Gels

View full text Add to dashboard Cite

Drug delivery is a fascinating research field with several development opportunities. Great attention is now focused on colloidal systems, nanoparticles, and nanogels and on the possibility of modifying them in order to obtain precise targeted drug delivery systems. The aim of this review is to give an overview of the main available surface functionalization and coating strategies that can be adopted in order to modify the selectivity of the nanoparticles in the delivery process and obtain a final system with great targeted drug delivery ability. We also highlight the most important fields of application of these kinds of delivery systems and we propose a comparison between the advantages and disadvantages of the described functionalization strategies.

show abstract

“…Targeting the molecules that modulate leukocyte traffic has recently become a popular approach for drug delivery. 60 NPs that mimic the structures of these ligands have been designed to attach to endothelial cells and release drugs to the adjacent immune cells. For example, recombinant P-selectin glycoprotein ligand-1 (PSGL-1) was conjugated to PEGylated PLA particles, and the synthesized NPs demonstrated a significantly stronger ability to adhere to the inflamed endothelium in an in vivo model, compared to unconjugated PEG-PLA particles.…”

Section: Immune Cells the Lamina Propria And The Extracellular Matrixmentioning

confidence: 99%

<p>Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives</p>

Yang¹,

Merlin²

2019

IJN

116

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), which mainly consists of Crohn's disease and ulcerative colitis, is a chronic and relapsing inflammatory condition of the gastrointestinal tract. The traditional treatment strategies relied on frequent administration of high dosages of medications, including antibiotics, non-steroidal anti-inflammatory drugs, biologics, and immunomodulators, with the goal of reducing inflammation. Some of these medications were effective in alleviating the early-stage inflammatory symptoms, but their long-term efficacies were compromised by the accumulation of toxicities. Recently, nanoparticle (NP)based drugs have been widely studied for their potential to solve such problems. Various mechanisms/strategies, including size-, charge-, pH-, pressure-, degradation-, ligand-receptor-, and microbiome-dependent drug delivery systems, have been exploited in preclinical studies. A certain number of NP delivery systems have sought to target drugs to the inflamed intestine. Although several NP-based drugs have entered clinical trials for the treatment of IBD, most have failed due to premature drug release, weak targeting ability, and the high immune toxicity of some of the synthetic nanomaterials that have been used to fabricate the NPs. Therefore, there is still a need for rationally designed and stable NP drug delivery system that can specifically target drugs to the disease site, prolong the drug's residence time, and minimize systemic side effects. This review will analyze the current state of the art in NP-mediated drug delivery for IBD treatment. We will focus on topics such as deliverable targets (at the tissue or cellular level) for treating inflammation; the target-homing NP materials that can interact with such targets; and the major administration routes for treating IBD. These discussions will integrate notable trends in the research and development of IBD medications, including multi-responsive NP-mediated delivery and naturally-derived targeting NPs. Finally, current challenges and future directions will be presented in the hopes of advancing the study of NP-mediated strategies for treating IBD.

show abstract

Biomimetic nanoparticles for inflammation targeting

Cited by 267 publications

References 101 publications

Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source

Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source

Coating and Functionalization Strategies for Nanogels and Nanoparticles for Selective Drug Delivery

<p>Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives</p>

Contact Info

Product

Resources

About